United Therapeutics’ PHINDER Study: A Step Forward in Early Detection of Pulmonary Hypertension

United Therapeutics Corp. ((UTHR)) announced an update on their ongoing clinical study.

United Therapeutics Corp. is conducting a study titled ‘Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection (PHINDER).’ The study aims to evaluate screening strategies for pulmonary hypertension in patients with interstitial lung disease, which could lead to earlier detection and treatment of this serious condition.

The intervention being tested is a procedure called Right Heart Catheterization (RHC), which is used to assess pulmonary hemodynamics in patients. This procedure is crucial for diagnosing pulmonary hypertension.

The study is observational, following a cohort model with a prospective time perspective. All enrolled patients will receive the RHC procedure, and the study is open-label and non-randomized.

The study began on March 1, 2023, with an estimated completion date of June 27, 2025. The last update was submitted on June 27, 2025, indicating the study is actively recruiting participants.

This study could have significant market implications for United Therapeutics, potentially boosting investor confidence and stock performance if the screening strategy proves effective. It also positions the company strategically within the pulmonary hypertension treatment market.

The PHINDER study is ongoing, with further details available on the ClinicalTrials portal.